Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026

Takeda (TSE:4502/NYSE:TAK) announced detailed results from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase], which, if approved, has the potential to become the first facilitated SCIG 20% therapy for patients with Primary Immunodeficiency Disease (PID) administered up to once-monthly (every 3 to 4 weeks). Data in participants aged 16 years and older are featured in two late-breaking posters at the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID 2026) in Maastricht, the Netherlands.

Previously shared topline results showed the clinical trial met its primary endpoint, demonstrating pharmacokinetic (PK) comparability between TAK-881 and HYQVIA^® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]. Secondary analyses showed TAK-881 demonstrated infection outcomes and safety and tolerability profiles consistent with established IG therapy standards in participants aged 16 years and older.

For many patients with PID, lifelong immunoglobulin replacement therapy is required to help maintain protective antibodies against infections.¹ Although established IG therapies provide proven protection, high frequency, high infusion volumes and/or extended administration times can impose a significant therapeutic burden.²

The newly presented data showed TAK-881 delivered the same IG dose in 50% less volume with median infusion times shortened by 56.2 minutes (42.6%) for one infusion site versus HYQVIA, while maintaining up to once-monthly dosing. These results support the potential of TAK-881 to offer patients with PID an alternative treatment option that may help reduce aspects of treatment burden associated with infusion volume, duration and infusion-site requirements while maintaining the safety, efficacy and tolerability of IG therapies.

“Reducing the administrative treatment burden is crucial for patients with primary immunodeficiency who often face lifelong immunoglobulin replacement,” said Dr. Jolan Walter, MD, PhD, Division Chief of Pediatric Allergy & Immunology at University of South Florida and Johns Hopkins All Children's Hospital.* “By halving infusion volume, the facilitated SCIG 20% meaningfully shortened administration times while maintaining once-monthly dosing – delivering consistent protection while potentially giving patients back time.”

The TAK-881-3001 clinical trial evaluated the PK, efficacy, safety, tolerability and immunogenicity of TAK-881 in adult and pediatric patients aged 2 years and older with PID previously treated with IG therapy. Participants aged ≥16 years entered a randomized crossover comparison of TAK-881 and HYQVIA, while participants aged under 16 years received TAK-881 in a separate single-arm cohort.

New data from participants aged 16 years and older showed TAK-881:

• Achieved comparable PK: In addition to meeting its primary endpoint demonstrating equivalent immunoglobulin G (IgG) exposure between TAK-881 and HYQVIA, descriptive steady-state secondary pharmacokinetic parameters were consistent between TAK-881 and HYQVIA. Trough concentrations (geometric means: 11.7 vs. 11.9 g/L) were above accepted protective thresholds against infections.
  
  
• Reduced infusion duration and volume: Delivering equivalent bodyweight-adjusted IG dosing in a concentrated 20% solution reduced total infusion volume by 50%. This volume reduction enabled shorter median infusion durations compared to HYQVIA whether using one infusion site (75.8 vs. 132 minutes; a 56.2-minute reduction) or two infusion sites (58.3 vs. 86 minutes; a 27.7-minute reduction), at a median maximum tolerated rate of 300 mL/hour/site.
  
  This reduced volume may support administration across fewer required infusion sites compared to HYQVIA. Treatment approaches that reduce infusion volume and duration may help reduce administration burden for patients managing long-term therapy, aiming to lessen the overall treatment burden for patients.
  
  
• Demonstrated infection protection: TAK-881 demonstrated comparable immune protection to HYQVIA based on descriptive analyses. Low annualized infection rates (mean [95% CI]: 2.62 [1.75–3.76] vs. 2.73 [1.85–3.86]) and a low annualized serious bacterial infection rate (mean [95% CI]: 0.0558 [0.0197-0.121]) were observed, while maintaining overall protective IgG trough levels throughout the study. No acute serious bacterial infections were reported during HYQVIA treatment.
  
  
• Demonstrated a comparable safety profile: TAK-881 was well tolerated with no new safety signals or TAK-881-related serious adverse events identified as compared to HYQVIA. Treatment-emergent adverse events (TEAEs) occurred in 56.1% (23/41) of participants on TAK-881 and 50.0% (19/38) on HYQVIA; TEAEs were mild to moderate, with no TAK‑881-related Grade ≥3 TEAEs. Overall, 9 of 43 randomized participants (20.9%) discontinued the study across both treatment periods. No TAK-881-related adverse events led to study discontinuation. Long-term safety continues to be evaluated in the ongoing TAK-881-3002 extension study.

“Building on the trusted clinical heritage of HYQVIA through insights shaped by our ongoing dialogue with the PID community, TAK-881 reflects our efforts to improve the day-to-day care experience for individuals with chronic immunodeficiencies,” said Kristina Allikmets, MD, PhD, Senior Vice President and Head of Plasma Derived Therapies R&D at Takeda. “If approved, TAK-881 would further strengthen our industry-leading immunoglobulin offering for immunodeficiencies by adding a more convenient administration option anchored in the proven efficacy and safety of our portfolio. We look forward to advancing TAK-881 through regulatory review and, if approved, bringing this innovation to patients.”

Takeda expects to submit applications for TAK-881 to regulatory authorities in the United States, European Union and Japan in fiscal year 2026.

About TAK-881-3001 and TAK-881-3002

TAK-881-3001 was a pivotal Phase 2/3 clinical trial evaluating the pharmacokinetics, efficacy, safety, tolerability and immunogenicity of TAK-881 in adults and pediatric patients aged 2 years and older with Primary Immunodeficiency Disease (PID) who were previously treated with immunoglobulin (IG) therapy. Study participants aged 16 and older were randomized to be treated with TAK-881 followed by HYQVIA or HYQVIA followed by TAK-881 with the same dose and dosing interval of IG for up to 51 weeks in the open label, randomized cross-over study part. Participants aged 2 to < 16 were treated with only TAK-881 for up to 27 weeks in the open label single-arm study part. Further information about the TAK-881-3001 clinical trial is available at ClinicalTrials.gov under study identifier NCT05755035.

TAK-881-3002 is a Phase 3 study evaluating the long-term safety and tolerability of TAK-881 in patients with PID and is the extension study of TAK-881-3001. Further information about the TAK-881-3002 clinical trial is available at ClinicalTrials.gov under study identifier NCT06076642.

About TAK-881

TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase] is an investigational liquid medicine comprised of one vial of immunoglobulin (IG) 20% and one vial of Halozyme’s recombinant human hyaluronidase (rHuPH20). IG is collected from human plasma and maintains the body’s immune system. TAK-881 is infused under the skin into the fatty subcutaneous tissue where the hyaluronidase facilitates the dispersion and increases the absorption of immunoglobulin in the subcutaneous tissue, allowing larger volumes to be infused at a given infusion site. As a SCIG 20% facilitated with hyaluronidase, TAK-881 is being developed with the goal of reducing infusion volume and duration while providing effective immune protection for patients with PID.

About Primary Immunodeficiency Disease (PID)

Primary Immunodeficiency Disease (PID) is a group of more than 550 rare and chronic disorders, where a part of the body’s immune system is missing or does not function the way it should.³ These conditions result from genetic mutations, which are usually inherited.⁴ The symptoms of PID vary and can include frequent and/or persistent infections and unusual autoimmunity, often leading to prolonged periods of misdiagnosis despite consultations with multiple specialists.⁵ In the United States, PID affects about 1 in 1,200 people.⁶

About HYQVIA^®

HYQVIA^® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is a liquid medicine containing immunoglobulin (IG) 10% and Halozyme’s recombinant human hyaluronidase (rHuPH20). HYQVIA is approved by the European Medicines Agency (EMA) as a replacement therapy in adults, children and adolescents (0-18 years) with Primary Immunodeficiency Disease (PID) with impaired antibody protection and with Secondary Immunodeficiency Disease (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF) or serum IgG level of <4 g/L. In addition, it is approved by the EMA in adults, children and adolescents (0-18 years) with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy after stabilization with intravenous IG therapy (IVIG).

In the United States, HYQVIA is approvedto treat adults and children two years of age and older with PID and as a maintenance therapy for adult patients with CIDP.

HYQVIA is infused under the skin into the fatty subcutaneous tissue and contains IG collected from human plasma. IGs are antibodies that maintain the body’s immune system. The hyaluronidase part of HYQVIA facilitates the dispersion and absorption of IG in the subcutaneous space between the skin and the muscle. HYQVIA is infused up to once a month (every two, three or four weeks for CIDP; every three or four weeks for PID).

HyQvia^® (Human normal immunoglobulin) 100 mg/ml solution for infusion for subcutaneous use

Important Safety Information (European Union)

Please consult the HyQvia (Human normal immunoglobulin (SCIg)) Summary of Product Characteristics (SmPC) before prescribing, particularly in relation to dosing and treatment monitoring.

GUIDANCE FOR USE: Therapy should be initiated and monitored under the supervision of a physician experienced in the treatment of immunodeficiency/CIDP. The medicinal product should be administered via the subcutaneous (SC) route. The dose and dose regimens are dependent on the indication. The dose may need to be individualized for each patient dependent on the PK and clinical response. Dose based on bodyweight may require adjustment in underweight or overweight patients.

CONTRAINDICATIONS: Not be given intravenously or intramuscularly. Hypersensitivity to the active substance or to any of the excipients. Hypersensitivity to human immunoglobulins, especially in very rare cases of IgA deficiency when the patient has antibodies against IgA. Systemic hypersensitivity to hyaluronidase or rHuPH20.

SPECIAL POPULATIONS: Paediatric population: The dosing schedule for children and adolescents (0 to 18 years) for replacement and immunomodulatory therapies is the same as for adults. The warnings and precautions listed in the SmPC apply both to adults and children. Pregnancy: the safety of this medicinal product for use in human pregnancy has not been established in controlled clinical studies and therefore should only be given with caution to pregnant women and breast-feeding mothers. Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are to be expected. Fertility: there are currently no clinical safety data available. Clinical experience with immunoglobulins suggests that no harmful effects on fertility are to be expected.

SPECIAL WARNINGS AND PRECAUTIONS FOR USE: Traceability: in order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. Precautions for use: if HyQvia is accidentally administered into a blood vessel, patients could develop shock; Certain adverse reactions may occur more frequently in patients who receive human normal immunoglobulin for the first time or, in rare cases, when the human normal immunoglobulin product is switched or when there has been a long interval since the previous infusion; potential complications can often be avoided by initially infusing the product slowly and ensuring that patients are carefully monitored. All other patients should be observed for at least 20 minutes after the administration. When treatment is given at home, support from another responsible person should be available. Patients on self-home treatment and/or their guardian should also be trained to detect early signs of hypersensitivity. In case of adverse reaction, either the rate of administration must be reduced, or the infusion stopped. No chronic changes in the skin were observed in the clinical studies. Patients should be reminded to report any chronic inflammation, nodules or inflammation that occurs at the infusion site and lasts more than a few days. Hypersensitivity to IG 10%:Patients with anti-IgA antibodies, in whom treatment with SCIg products remains the only option, should be treated with HyQvia only under close medical supervision. Rarely, human normal immunoglobulin can induce a fall in blood pressure with anaphylactic reaction, even in patients who had tolerated previous treatment with human normal immunoglobulin, please read the SmPC for more information. Hypersensitivity to rHuPH20: any suspicion of allergic or anaphylactic like reactions following rHuPH20 administration requires immediate discontinuation of the infusion and standard medical treatment should be administered, if necessary. Immunogenicity of rHuPH20: development of non-neutralizing antibodies and neutralizing antibodies to the rHuPH20 component has been reported in patients receiving HyQvia in clinical studies. Arterial and venous thromboembolic events have been associated with the use of immunoglobulins. Patients should be sufficiently hydrated before using immunoglobulins. Caution should be exercised in patients with pre-existing risk factors for thromboembolic events. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. Thrombosis may also occur in the absence of known risk factors. Patients should be informed about first symptoms of thromboembolic events and be advised to contact their physician immediately upon onset of symptom. Haemolytic anaemia: immunoglobulin products contain antibodies to blood groups (e.g. A, B, D) which may act as haemolysins. Immunoglobulin product recipients should be monitored for clinical signs and symptoms of haemolysis. Aseptic meningitis syndrome (AMS): it has been reported to occur in association with IVIg and SCIg treatment; the symptoms usually begin within several hours to 2 days following immunoglobulin treatment. Patients should be informed about the first symptoms. Discontinuation of immunoglobulin treatment may result in remission of AMS within several days without sequelae. AMS may occur more frequently in association with high-dose (2 g/kg) IVIg treatment. From post-marketing data no clear correlation of AMS to higher doses was observed. Higher incidences of AMS were seen in women. Interference with serological testing: After infusion of immunoglobulins, the transitory rise of the various passively transferred antibodies in the patient’s blood may result in misleading positive results in serological testing. Infusions of immunoglobulin products may lead to false positive readings in assays that depend on detection of β-D-glucans for diagnosis of fungal infections. Transmissible agents: standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infectious agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens. The measures taken are considered effective for enveloped and for the non-enveloped viruses.

INTERACTIONS: Live attenuated virus vaccines Immunoglobulin administration may impair for a period of at least 6-weeks and up to 3-months the efficacy of live attenuated virus vaccines. After administration of this medicinal product, an interval of 3-months should elapse before vaccination with live attenuated virus vaccines. In the case of measles, this impairment may persist for up to 1 year. Therefore, patients receiving measles vaccine should have their antibody status checked.

UNDESIRABLE EFFECTS: The most frequently reported adverse reactions (Ars) were local reactions. The most frequently reported systemic Ars were headache, fatigue, nausea, and pyrexia. The majority of these Ars were mild to moderate. Cases of transient aseptic meningitis, transient haemolytic reactions, increase in serum creatinine level and/or acute renal failure have been observed with human normal immunoglobulin. ADRs frequency per infusion: very common (≥ 1/10): Local reactions (Total, see SmPC for the detailed list of local reactions); common (≥ 1/100 to < 1/10): Headache, Nausea, Abdominal pain, Abdominal pain lower, Abdominal pain upper and Abdominal tenderness, Erythema, Asthenia, Fatigue, Lethargy and Malaise; uncommon (≥ 1/1 000 to < 1/100): Dizziness, Migraine, Tremor, Paraesthesia, Sinus tachycardia and Tachycardia, Blood pressure increased and Hypertension, Diarrhoea, Vomiting, Abdominal distension, Pruritus, Rash, Rash erythematous, Rash macular, Rash maculo-papular and Rash papula, Urticaria, Myalgia, Arthralgia, Limb discomfort and Pain in extremity Back pain, Joint stiffness, Musculoskeletal chest pain, Chills, Oedema, Oedema peripheral and Swelling (systemic), Localised oedema, Peripheral swelling and Skin oedema, Gravitational oedema, Oedema genital, Scrotal swelling and Vulvovaginal swelling, Burning sensation; rare (≥ 1/10 000 to < 1/1 000): Cerebrovascular accident and Ischaemic stroke, Hypotension, Dyspnoea, Groin pain, Haemosiderinuria, Hyperhidrosis, Coombs direct test positive and Coombs test positive.

For EU SmPC, please visit:https://www.ema.europa.eu/en/documents/product-information/hyqvia-epar-product-information_en.pdf

For U.S. full Prescribing Information, please visit:https://www.shirecontent.com/PI/PDFs/HYQVIA_USA_ENG.pdf

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

_______________________________

*Dr. Walter’s comments are made in an individual capacity. Any statements or opinions expressed are her own and should not be construed as representing the views of the University of South Florida or Johns Hopkins All Children's Hospital.

1 Gardulf A. Immunoglobulin treatment for primary immunodeficiencies: advantages of subcutaneous replacement therapy. BioDrugs. 2007;21(2):105-116.

2 Jones GL, Vogt KS, Chambers D, Clowes M, Shrimpton A. What is the burden of immunoglobulin replacement therapy in adult patients with primary immunodeficiencies? A systematic review. Front Immunol. 2018;9:1308. doi:10.3389/fimmu.2018.01308.

3 Immune Deficiency Foundation. Living With Primary Immunodeficiency. Accessed September 2026. Available at: https://primaryimmune.org/living-primary-immunodeficiency.

4 Center for Disease Control and Prevention. About Primary Immunodeficiency (PI). Accessed September 2026. Available at: https://www.cdc.gov/primary-immunodeficiency/about/index.html.

5 Immune Deficiency Foundation. Understanding Primary Immunodeficiency. Accessed September 2026. Available at: https://primaryimmune.org/understanding-primary-immunodeficiency.

6 Kobrynski L, Powell RW, Bowen S. J Clin Immunol. 2014;34(8):954-961.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261014178348/en/